Ibex Medical Analytics Enters Collaboration with AstraZeneca and Daiichi Sankyo to Develop AI-based HER2 Scoring Product
Ibex: Our AI Algorithm to Aid Pathologists with Accurate and Reproducible HER2 and HER2-low Assessment in Breast Cancer Diagnosis
TEL AVIV, Israel, Jan. 24, 2023 /PRNewswire/ — Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced an agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients.
Scoring of HER2 (human epidermal growth factor receptor 2) protein expression in breast cancer is used to identify patients who are likely to benefit from HER2-directed therapies. Currently, pathologists routinely score HER2 in tumor samples visually using a microscope, which can be challenging in cases of low HER2 expression as scoring is subjective and may lead to varied interpretations. Computational tools developed using Artificial Intelligence have the potential to support pathologists in accurate and objective scoring of HER2, which can help oncologists in selecting therapies that are approved for treating patients with HER2-positive or HER2-low breast cancer.
“Recognizing the vital role pathologists play in the diagnosis and treatment of cancer patients, we are thrilled to partner with AstraZeneca and Daiichi Sankyo to clinically validate our automated HER2 scoring product and offer it to laboratories around the world,” said Joseph Mossel, Co-founder and CEO of Ibex Medical Analytics. “As the most commonly diagnosed cancer in women, this collaboration will allow pathologists to utilize our technology to optimize breast cancer diagnosis and ultimately improve the identification of patients eligible for HER2-directed therapy.”
Ibex’s Galen™ Breast HER2 is an IHC scoring product that detects tumor areas and quantifies HER2 expression into four standard categories, 0, 1+, 2+ and 3+, based on the 2018 ASCO/CAP scoring guidelines1. As part of this collaboration, Ibex will work with AstraZeneca and Daiichi Sankyo to develop and clinically validate its HER2 IHC scoring product and generate evidence that further supports adoption of the technology.
A multi-site validation study on Galen Breast HER2 involved a cohort of 453 breast tumors of diverse subtypes. The study demonstrated that Galen’s AI algorithm provides an accurate and automated HER2 score for pathologists and was recently presented at the San Antonio Breast Cancer Symposium2.
Beyond this collaboration, Ibex supports pathologists with AI-based diagnostic solutions that help detect and grade different types of invasive and non-invasive breast cancer and other tumor types, and are used in everyday practice in laboratories, hospitals and health systems worldwide. Ibex’s Galen Breast solution demonstrated robust outcomes in detecting and grading multiple types of breast cancer and other clinically relevant features across clinical studies performed on numerous diagnostic workflows, one of which was recently published in Nature’s peer-reviewed npj Breast Cancer journal3,4.
In addition to HER2, Ibex is further expanding Galen Breast to include automated quantification of additional IHC-stained slides, such as ER, PR and Ki-67, intended to provide pathologists with a comprehensive set of tools for breast cancer diagnosis. With these expanded capabilities, Galen Breast may further enhance diagnostic efficiency and enable more accurate and objective scoring of breast biomarkers, improving treatment decisions and patient care.
About Ibex Medical Analytics
Ibex Medical Analytics (Ibex) is transforming cancer diagnostics with world-leading, clinical grade AI-powered solutions, empowering physicians to provide accurate, timely and personalized cancer diagnosis for every patient. Our Galen™ suite of solutions is the first and most widely deployed AI-technology in pathology and is used as part of everyday routine, supporting pathologists and providers worldwide in improving the quality and accuracy of diagnosis, implementing comprehensive quality control, reducing turnaround times and boosting productivity with more efficient workflows. Ibex’s Artificial Intelligence technology is built on Deep Learning algorithms trained by a team of pathologists, data scientists and software engineers. For additional company information, please visit https://ibex-ai.com/ and follow us on LinkedIn and Twitter.
The Galen™ suite includes certain solutions which are CE marked and registered with the UK MHRA. The solutions are for Research Use Only (RUO) in the United States and not cleared by the FDA. For more information, including indication for use and regulatory approval in other countries, contact Ibex Medical Analytics.
Media Contacts
Ibex Medical Analytics
Nechama Rosengarten
FINN Partners
Nechama.rosengarten@finnpartners.com
+1-929-222-8006
[1] Wolff et al, Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 142:1364-1382, 2018.
[2] Globerson et al, A fully automatic artificial intelligence system for accurate and reproducible HER2 IHC scoring in breast cancer. San Antonio Breast Cancer Symposium 2022. https://ibex-ai.com/wp-content/uploads/2022/12/Ibex_HER2_at_SABCS_2022_poster.pdf
[3] Sandbank et al., Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies; npj Breast Cancer 8, 129 (2022) https://doi.org/10.1038/s41523-022-00496-w
[4] Vincent-Salomon et al., Primary Diagnosis of Breast Biopsies supported by AI versus Microscope: Multi-Site Clinical Reader Study. San Antonio Breast Cancer Symposium 2022. https://ibex-ai.com/wp-content/uploads/2022/12/Ibex_poster_Galen_Breast_San_Antonio.pdf
Logo – https://mma.prnewswire.com/media/1839936/Ibex_Logo.jpg
SOURCE: Cision PR Newswire
